• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

    3/12/25 4:16:00 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email

    STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025.

    Kewaunee Scientific Corporation (PRNewsFoto/Kewaunee Scientific Corporation)

    Fiscal Year 2025 Third Quarter Results:

    Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter. EBITDA1 for the quarter was $3,734,000 compared to $4,414,000 for the prior year quarter. Diluted earnings per share were $0.45 compared to diluted earnings per share of $0.85 in the prior year quarter.

    Within the third quarter there were costs associated with the acquisition and integration of Nu Aire by Kewaunee Scientific Corporation. Additionally, results were impacted by transaction accounting related to the write-up of various assets on Nu Aire's books. We believe communicating these impacts and reporting adjusted financial metrics helps investors better understand our financial performance.

    Consolidated Results Adjusted for Professional and Other Fees Related to the Nu Aire Transaction, Integration, and Purchase Accounting - Acquisition, integration and purchase accounting costs in the aggregate in quarter three were a $2,514,000 impact to pre-tax earnings and a $1,994,000 impact to EBITDA. After adjusting for these costs, adjusted pre-tax earnings for the quarter were $3,789,000 compared to $3,515,000 for the prior year quarter, an increase of 7.8%. Adjusted net earnings were $3,258,000 compared to net earnings of $2,521,000 for the prior year quarter. Adjusted EBITDA for the quarter was $5,728,000 compared to $4,414,000 for the prior year quarter. Adjusted diluted earnings per share were $1.09 compared to diluted earnings per share of $0.85 in the prior year quarter. Further details are presented in the Adjusted Consolidated Statement of Operations Reconciliation schedule.

    The Company's order backlog was $221.6 million on January 31, 2025, as compared to $152.3 million on January 31, 2024, and $155.6 million on April 30, 2024.

    Nu Aire Acquisition Update - Kewaunee successfully completed the acquisition of Nu Aire, Inc. on November 1, 2024, marking a significant milestone in our strategic growth initiatives. This quarter represents the first time Nu Aire's financial results will be integrated into Kewaunee's consolidated financial statements and order backlog, with its performance reported within the Company's Domestic segment.

    Domestic Segment - Domestic sales for the quarter were $51,976,000, an increase of 63.6% from sales of $31,774,000 in the prior year quarter. Domestic segment net earnings were $2,876,000 compared to $2,633,000 in the prior year quarter. Domestic segment EBITDA was $5,249,000 compared to $3,832,000 for the prior year quarter. The increase in Domestic sales and earnings was driven by higher manufacturing volumes than the prior year period and the incorporation of Nu Aire's results.

    International Segment - International sales for the quarter were $15,191,000, an increase of 1.2% from sales of $15,004,000 in the prior year quarter. International segment net earnings were $476,000 compared to $923,000 in the prior year quarter. International segment EBITDA was $760,000 compared to $1,676,000 for the prior year quarter. Kewaunee's International segment continues to be challenged by customer site delays impacting billings.

    Corporate Segment – Corporate segment pre-tax net loss was $3,025,000 for the quarter, as compared to a pre-tax net loss of $1,069,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,275,000) compared to corporate segment EBITDA of ($1,094,000) for the prior year quarter. The change in EBITDA was primarily driven by an increase in professional service and other fees during the quarter related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024, and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness.

    Total cash on hand on January 31, 2025, was $12,335,000, as compared to $25,938,000 on April 30, 2024. Working capital was $58,441,000, as compared to $54,014,000 at the end of the third quarter last year and $56,037,000 on April 30, 2024.

    The Company had short-term debt of $1,131,000 as of January 31, 2025, as compared to $3,099,000 on April 30, 2024. Long-term debt was $65,819,000 on January 31, 2025, as compared to $28,479,000 on April 30, 2024. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $27,604,000 of the long-term debt on January 31, 2025, and $28,133,000 of the long-term debt on April 30, 2024. Long-term debt, net of the sale-leaseback transaction, was $38,215,000 on January 31, 2025, as compared to $346,000 on April 30, 2024. The Company's debt-to-equity ratio on January 31, 2025, was 1.29-to-1, as compared to 0.70-to-1 on April 30, 2024. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on January 31, 2025, was 0.84-to-1, as compared to 0.20-to-1 on April 30, 2024.

    "Kewaunee delivered another strong quarter, demonstrating once again our positive momentum in the marketplace and our continued operational performance improvement," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Our strategy to emphasize investments in our manufacturing assets, while strengthening our dealer and distribution relationships is working."

    "In our Domestic segment, we achieved solid gains compared to the prior year. These gains were driven by sustained product demand in the U.S., where we leverage our market position as the industry's leader."

    "In India, where our backlog is at a record high, revenue has been slowed due to construction site delays. We are working closely with our customers to ensure seamless execution when project sites are ready. This will result in favorable revenue and earnings for us."

    Hull continued, "Kewaunee's backlog stands at a robust $222 million, highlighting the strength, stability, and diversity of the markets we serve. Our products support a broad range of critical industries - including life sciences, industrial, healthcare, pharmacy, education, petrochemical, and government research. These sectors are foundational to economic progress, scientific discovery, and innovation, and they benefit from long-term structural growth trends fueled by both private and public investment. Our strong backlog is a testament to Kewaunee's ability to meet evolving customer needs and reinforces our position as a trusted partner in advancing global research and innovation."

    "Over the past five years, we have taken deliberate steps to strengthen our supply chain and mitigate risks to ensure resiliency amid market fluctuations. As the largest U.S.-based manufacturer of laboratory products and technical furniture, Kewaunee is uniquely positioned to provide stability and certainty to customers requiring reliable, domestically produced solutions. Additionally, we have built a robust and diversified global supply chain, ensuring access to critical materials through multiple sourcing strategies. These strategic initiatives enhance our ability to consistently deliver high-quality products while mitigating against supply chain disruptions, tariffs, and other external challenges."

    "To provide greater transparency into our financial performance, we have included an exhibit detailing the reconciliation from EBITDA to adjusted EBITDA. This analysis isolates transaction, integration, and other related costs, providing a clearer picture of Kewaunee's ongoing earnings power post-integration of the Nu Aire acquisition."

    "Looking ahead, we are focused on delivering a strong finish to fiscal year 2025. Our teams remain committed to operational excellence, customer success, and driving sustainable growth. We continue to invest in our partnerships, ensuring our channel partners have the support they need to win in the marketplace. With strong fundamentals, a growing backlog, and a clear strategic vision, Kewaunee is well-positioned to capitalize on future opportunities and create lasting value for our shareholders."

    1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

     

    EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation

    (Unaudited)

    ($ in thousands)

     

    Quarter Ended January 31, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  2,633



    $                     923



    $                (1,035)



    $                  2,521

    Add/(Less):

















    Interest Expense



    321



    72



    18



    411

    Interest Income



    —



    (220)



    (97)



    (317)

    Income Taxes



    220



    796



    (34)



    982

    Depreciation and Amortization



    658



    105



    54



    817

    EBITDA



    $                  3,832



    $                  1,676



    $                (1,094)



    $                  4,414



















    Quarter Ended January 31, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  2,876



    $                     476



    $                (1,998)



    $                  1,354

    Add/(Less):

















    Interest Expense



    322



    26



    789



    1,137

    Interest Income



    (1)



    (130)



    (81)



    (212)

    Income Taxes



    638



    281



    (1,027)



    (108)

    Depreciation and Amortization



    1,414



    107



    42



    1,563

    EBITDA



    $                  5,249



    $                     760



    $                (2,275)



    $                  3,734

    Professional & Other Fees2



    1,012



    —



    982



    1,994

    Adjusted EBITDA



    $                  6,261



    $                     760



    $                (1,293)



    $                  5,728



















    Year to Date January 31, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  8,398



    $                  1,917



    $                (2,588)



    $                  7,727

    Add/(Less):

















    Interest Expense



    1,024



    143



    46



    1,213

    Interest Income



    —



    (638)



    (120)



    (758)

    Income Taxes



    2,365



    2,257



    (728)



    3,894

    Depreciation and Amortization



    1,853



    302



    150



    2,305

    EBITDA



    $                13,640



    $                  3,981



    $                (3,240)



    $                14,381



















    Year to Date January 31, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                10,271



    $                  1,295



    $                (5,011)



    $                  6,555

    Add/(Less):

















    Interest Expense



    1,176



    66



    809



    2,051

    Interest Income



    (1)



    (437)



    (410)



    (848)

    Income Taxes



    2,643



    807



    (2,450)



    1,000

    Depreciation and Amortization



    2,736



    317



    131



    3,184

    EBITDA



    $                16,825



    $                  2,048



    $                (6,931)



    $                11,942

    Professional & Other Fees3



    1,012



    —



    3,253



    4,265

    Adjusted EBITDA



    $                17,837



    $                  2,048



    $                (3,678)



    $                16,207



    2 Professional and other fees incurred during the three months ended January 31, 2025 related to the Company's acquisition of Nu

    Aire, Inc. ("Nu Aire"), which closed on November 1, 2024, and related purchase accounting

    3 Professional and other fees incurred during the nine months ended January 31, 2025 related to the Company's acquisition of Nu

    Aire and related purchase accounting

     

    Adjusted Consolidated Statement of Operations Reconciliation

    (Unaudited)

    ($ in thousands, except per share amounts)



    Three Months Ended January 31,



    As Reported

    2025



    Professional

    & Other Fees4



    Adjusted

    2025



    2024

    Net sales

    $      67,167



    $              —



    $       67,167



    $      46,778

    Cost of products sold

    48,788



    854



    47,934



    34,749

    Gross profit

    18,379



    854



    19,233



    12,029

    Operating expenses

    16,129



    1,660



    14,469



    8,223

    Operating profit

    2,250



    2,514



    4,764



    3,806

    Pension expense

    —



    —



    —



    (41)

    Other income, net

    162



    —



    162



    161

    Interest expense

    (1,137)



    —



    (1,137)



    (411)

    Profit before income taxes

    1,275



    2,514



    3,789



    3,515

    Income tax (benefit) expense

    (108)



    610



    502



    982

    Net earnings

    1,383



    1,904



    3,287



    2,533

    Less: Net earnings attributable to the non-controlling interest

    29



    —



    29



    12

    Net earnings attributable to Kewaunee Scientific Corporation

    $         1,354



    $         1,904



    $         3,258



    $         2,521

















    Net earnings per share attributable to Kewaunee Scientific

    Corporation stockholders















    Basic

    $           0.47



    $           0.66



    $           1.13



    $           0.87

    Diluted

    $           0.45



    $           0.64



    $           1.09



    $           0.85



















    Nine Months Ended January 31,



    As Reported

    2025



    Professional

    & Other Fees5



    Adjusted

    2025



    2024

    Net sales

    $    163,324



    $              —



    $     163,324



    $    147,053

    Cost of products sold

    118,505



    854



    117,651



    109,642

    Gross profit

    44,819



    854



    45,673



    37,411

    Operating expenses

    35,560



    3,606



    31,954



    24,688

    Operating profit

    9,259



    4,460



    13,719



    12,723

    Pension expense

    —



    —



    —



    (122)

    Other income, net

    428



    324



    752



    384

    Interest expense

    (2,051)



    —



    (2,051)



    (1,213)

    Profit before income taxes

    7,636



    4,784



    12,420



    11,772

    Income tax expense

    1,000



    1,161



    2,161



    3,894

    Net earnings

    6,636



    3,623



    10,259



    7,878

    Less: Net earnings attributable to the non-controlling interest

    81



    —



    81



    151

    Net earnings attributable to Kewaunee Scientific Corporation

    $         6,555



    $         3,623



    $       10,178



    $         7,727

















    Net earnings per share attributable to Kewaunee Scientific

    Corporation stockholders















    Basic

    $           2.29



    $            1.27



    $            3.55



    $           2.68

    Diluted

    $           2.20



    $            1.22



    $            3.42



    $           2.64

    4 Professional and other fees incurred during the three months ended January 31, 2025 related to the Company's acquisition of Nu

    Aire and related purchase accounting, including the estimated tax impact

    5 Professional and other fees incurred during the nine months ended January 31, 2025 related to the Company's acquisition of Nu

    Aire and related purchase accounting and costs incurred related to the early termination of the Company's Revolving Credit

    Facility, including the estimated tax impact of both transactions

     

    About Non-GAAP Measures

    The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the acquisition of Nu Aire, Inc. and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

    EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's acquisition of Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the professional fees not related to our core business incurred during the current period, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

    About Kewaunee Scientific

    Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. 

    Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

    Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/.  

    This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2024, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Kewaunee Scientific Corporation

    Condensed Consolidated Statements of Operations

    (Unaudited)

    ($ and shares in thousands, except per share amounts)





    Three Months Ended

    January 31,



    Nine Months Ended

    January 31,



    2025



    2024



    2025



    2024

    Net sales

    $       67,167



    $       46,778



    $     163,324



    $     147,053

    Cost of products sold

    48,788



    34,749



    118,505



    109,642

    Gross profit

    18,379



    12,029



    44,819



    37,411

    Operating expenses

    16,129



    8,223



    35,560



    24,688

    Operating profit

    2,250



    3,806



    9,259



    12,723

    Pension expense

    —



    (41)



    —



    (122)

    Other income, net

    162



    161



    428



    384

    Interest expense

    (1,137)



    (411)



    (2,051)



    (1,213)

    Profit before income taxes

    1,275



    3,515



    7,636



    11,772

    Income tax (benefit) expense

    (108)



    982



    1,000



    3,894

    Net earnings

    1,383



    2,533



    6,636



    7,878

    Less: Net earnings attributable to the non-controlling interest

    29



    12



    81



    151

    Net earnings attributable to Kewaunee Scientific Corporation

    $          1,354



    $          2,521



    $          6,555



    $          7,727

















    Net earnings per share attributable to Kewaunee Scientific Corporation

    stockholders















    Basic

    $            0.47



    $            0.87



    $            2.29



    $            2.68

    Diluted

    $            0.45



    $            0.85



    $            2.20



    $            2.64

    Weighted average number of common shares outstanding















    Basic

    2,872



    2,893



    2,864



    2,885

    Diluted

    2,995



    2,965



    2,979



    2,927

     

    Kewaunee Scientific Corporation

    Condensed Consolidated Balance Sheets

    ($ in thousands)





    January 31, 2025



    April 30, 2024



    (Unaudited)





    Assets







    Cash and cash equivalents

    $            9,454



    $           23,267

    Restricted cash

    2,881



    2,671

    Receivables, less allowances

    57,419



    45,064

    Inventories

    31,560



    20,679

    Prepaid expenses and other current assets

    7,298



    5,136

    Total Current Assets

    108,612



    96,817

    Net Property, Plant and Equipment

    23,849



    17,649

    Right of use assets

    13,974



    7,454

    Deferred income taxes

    3,883



    7,401

    Net Intangible assets

    18,216



    —

    Goodwill

    14,150



    —

    Other assets

    6,464



    5,445

    Total Assets

    $        189,148



    $         134,766









    Liabilities and Stockholders' Equity







    Short-term borrowings

    $            1,131



    $             3,099

    Current portion of lease obligations

    3,497



    2,234

    Current portion of financing liability

    769



    713

    Current portion of term loan

    3,000



    —

    Accounts payable

    24,530



    23,262

    Other current liabilities

    17,244



    11,472

    Total Current Liabilities

    50,171



    40,780

    Long-term portion of lease obligations

    9,700



    5,669

    Long-term portion of financing liability

    26,835



    27,420

    Long-term portion of seller note

    23,463



    —

    Long-term portion of term loan

    11,500



    —

    Other non-current liabilities

    5,358



    4,688

    Total Liabilities

    127,027



    78,557

    Kewaunee Scientific Corporation Equity

    60,801



    54,760

    Non-controlling interest

    1,320



    1,449

    Total Stockholders' Equity

    62,121



    56,209

    Total Liabilities and Stockholders' Equity

    $        189,148



    $         134,766

     

    Contact:

    Donald T. Gardner III



    704/871-3274

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-third-quarter-of-fiscal-year-2025-302400353.html

    SOURCE Kewaunee Scientific Corporation

    Get the next $KEQU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kewaunee Scientific Announces Amendment to Share Repurchase Program

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not

      3/12/25 5:08:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

      STATESVILLE, N.C., Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's produc

      2/26/25 5:21:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    SEC Filings

    See more
    • SEC Form SD filed by Kewaunee Scientific Corporation

      SD - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      5/9/25 10:54:08 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 144 filed by Kewaunee Scientific Corporation

      144 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      3/31/25 4:23:01 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 10-Q filed by Kewaunee Scientific Corporation

      10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      3/14/25 10:22:53 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      4/7/25 10:57:11 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/24/25 4:32:54 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/18/25 3:20:26 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      11/1/24 9:14:13 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 11:44:29 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 9:59:14 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Financials

    Live finance-specific insights

    See more
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

      STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

      12/11/24 4:04:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 1:33:49 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Russell John was granted 1,896 shares, increasing direct ownership by 6% to 34,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:58:43 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M was granted 1,896 shares, increasing direct ownership by 10% to 20,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:56:19 AM ET
      $KEQU
      Medical Specialities
      Industrials